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Aim: Gestational diabetes mellitus (GDM) is associated with cardiovascular diseases; however, the relationship
between epicardial fat thickness (EFT) and GDM remains unclear. The present study evaluates and compares
EFT using transthoracic echocardiography in pregnant women with GDM.
Materials and methods: This cross-sectional study included 129 pregnant women in the third trimester: 65 with
GDM (GDM group) and 64 with uncomplicated pregnancies (control group). As defined by the World Health
Organization, the diagnosis of GDM was based on an abnormal 2-h oral glucose tolerance test (OGTT) results.
We used echocardiography to measure EFT in blood samples for all the participants.
Results: The postprandial blood glucose level was significantly higher in the GDM group than in the control group
(P < 0.001). There were no significant differences in BMI, heart rate, systolic and diastolic blood pressure or lipid
parameters between the groups. In the GDM group, isovolumic relaxation time (IVRT) parameters were significantly
higher than in the control group. EFT was significantly higher in the GDM group (P < 0.001) and was correlated
with postprandial glucose, BMI, age, and heart rate in both the groups. Only postprandial glucose and BMI
remained significantly associated with EFT after multiple stepwise regression analysis.
Conclusion: Echocardiographically measured EFT was significantly higher in the patients with GDM. The findings
show that EFT was strongly correlated with postprandial glucose.
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Gestational diabetes mellitus (GDM) is impairment in
carbohydrate tolerance that begins or is recognized for
the first time during pregnancy [1]. It has an incidence
of 1-14% [2,3]. GDM is not just a pregnancy disorder,
but patients with GDM are also at risk of developing
type 2 diabetes mellitus (DM) postpartum [4]. The rela-
tionship between type 2 DM and cardiovascular diseases
is well-known [5-8]. Since, the preclinical markers of the
atherosclerotic process are observed just before the
development of type 2 DM, cardiovascular risk in
females can be complicated by GDM.
Epicardial fat tissue is an active tissue that originates
from the same embryogenic layer as visceral adipose tissue
and contributes to the energy supply of the heart and its
surrounding tissues, and secretes hormones adiponectin* Correspondence: doktorsinaninci@gmail.com
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unless otherwise stated.and leptin. Epicardial fat thickness (EFT) is associated
with the thickness of visceral fat tissue [9]. In addition to
being an anatomical barrier, epicardial fat tissue is also a
local reserve for proinflammatory cytokines [10] and is
related to obesity, hypertension, insulin resistance and
coronary artery disease [11-16]. Currently, EFT measure-
ment is performed via transthoracic echocardiography
(TTE), magnetic resonance imaging (MRI) and multi-slice
computed tomography (CT) [17]. Measurement of EFT
via TTE is quite easy and is used for cardiovascular risk
assessment in routine practice [18].
The increase in EFT is associated with an increase in
the incidence of insulin resistance and DM [11]; however,
the relationship between GDM and EFT has not yet been
evaluated. Since, GDM is associated with a decrease in
insulin sensitivity or increase in insulin resistance, EFT
measurement during the pregnancy can be a significant
determinant of GDM. The present study aimed to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ography in pregnant women with and without GDM.Materials and methods
The subjects were selected from pregnant women
referred to our clinics between January 2013 and August
2013 for routine pregnancy monitoring and were diagnosed
with GDM. OGTT was conducted in patients with blood
glucose levels over 140 mg/dL during 24–28 gestational
weeks. OGTT was measured one hour after the patients
were given water with 50 g glucose. Gestational diabetes
was diagnosed if any two of the following values were
found: fasting blood glucose levels ≥92 mg/dL, blood glu-
cose levels ≥180 mg/dL in the first hour and ≥153 mg/dL
during the second hour [19].
This study was approved by the local ethical committee.
All subjects who participated in the study were informed
about the study procedures and they signed an informed
consent. We excluded women with a history of any previ-
ous glucose impairment (type 1 diabetes, type 2 diabetes,
or gestational diabetes), previous or current blood pres-
sure disorders and heart arrhythmia. Moreover, subjects
with a history of the use of corticosteroids in the previous
three months, tocolytic drugs, and serious maternal ill-
nesses such as cancer, endocrinological disorders, chronic
inflammation (systemic lupus erythematosus and rheuma-
toid arthritis), and those who were carrying more than
one fetus, or had a liver or renal disease were also
excluded.
Detailed physical examination was performed, blood
pressure measurements were obtained and body mass
index (BMI) was calculated in all subjects. Echocardio-
graphic analyses were performed and blood samples
were obtained from all the subjects.Echocardiographic investigation
All of the participants underwent TTE using a VIVID 3
(General Electric) device. The patients were evaluated
while in the left lateral decubitus position following a
five-minute rest. As recommended by the American
Society of Echocardiography [20], left ventricle end-
diastolic and end-systolic diameters, and the left
ventricle ejection fraction (LVEF) were measured via
M-mode echocardiography using standard windows and
the parasternal long-axis view. Left ventricle systolic
functions, left ventricle wall movements, and mitral,
aortic, tricuspid, and pulmonary valve structures and
insufficiency were evaluated with a 2-dimensional color
Doppler ultrasonography. While examining diastolic
functions, transmitral flow samples were written at a
rate of 100 mm s−1 by placing the Pulse Wave (PW)
Doppler cursor 1 cm above the mitral annular line in
apical four-chamber sections.EFT was defined as the echo-free space between the
outer wall of the myocardium and the visceral layer of
the pericardium. EFT was measured perpendicularly
from the free wall of the right ventricle at end-diastole
in three cardiac cycles, as previously described [21,22].
The maximum EFT was measured from the point on the
free wall of the right ventricle along the midline of the
ultrasound beam perpendicular to the aortic annulus.
For mid-ventricular parasternal short-axis assessment,
maximum EFT was measured from the free wall of the
right ventricle along the midline of the ultrasound beam,
perpendicular to the intraventricular septum at the mid-
choral level and the tip of the papillary muscles as the
anatomic landmark. The intraobserver variability coeffi-
cient was calculated as 0.95.
Blood collection and measurement
Blood samples from All the participants were obtained
between 0800 and 1000 following 8–12 h of fasting. We
used 8-mL vacuum tubes with gel to collect blood
samples from antecubital veins. The samples were then
centrifuged at 4000 × g for 10 min to separate the serum.
Biochemical parameters were measured using an Abbott
ARCHITECT c8000 (Abbott Laboratories, USA) auto
analyzer and commercial kits. Hematological parameters
were examined using an Abbott CellDyn 3700 (Abbott
Laboratories, USA) device via the laser and impedance
method.
Statistical analysis
Statistical analyses were carried out using the Statistical
package for Social Sciences for Windows version 15.0
(SPSS, Chicago, IL, USA). Descriptive statistics for each
variable were determined. Results for continuous variables
were demonstrated as mean ± standard deviation. Statisti-
cally significant differences between groups were deter-
mined by the chi-square test for categorical variables and
unpaired Student’s t-test for continuous variables. Asso-
ciations between the variables were explored using the
Pearson correlation and Spearman’s rho (for data that were
not normally distributed). A multiple stepwise line regres-
sion analysis was used to determine the contribution of
various factors to EFT. Univariate analysis was performed
and variables with p < 0.10 were entered into a backward
stepwise multivariate logistic regression analysis to assess
independent predictor for the presence of GDM. A p-value
less than 0.05 was considered significant.
Results
The study included 129 pregnant women: 65 in the
GDM group and 64 in the control group. Mean age in the
GDM group was 29.7 ± 5.4 years versus 30.3 ± 4.4 years in
the control group (p = 0.65). Heart rate, BMI and systolic
and diastolic blood pressure measurements were not
Table 1 Baseline clinical and laboratory characteristics of study population and comparison between the groups
Variables GDM group (n: 65) Control group (n: 64) p-value
Age (year) 29.7 ± 5.4 30.3 ± 4.4 0.651
Body mass index (kg/m2) 27.4 ± 3.4 26.3 ± 3.4 0.082
Heart rate (beats/minute) 89.3 ± 11.5 88. 9 ± 7.3 0.695
Mean systolic blood pressure (mmHg) 112.3 ± 12.8 112.6 ± 13.1 0.551
Mean diastolic blood pressure (mmHg) 71.0 ± 9.7 69.7 ± 11.1 0.991
Serum glucose (mg/dL) 98.8 ± 14.8 89.1 ± 9.3 <0.001
Postprandial serum glucose (mg/dL) 192.4 ± 37.4 132.2 ± 8.7 <0.001
Triglyceride (mg/dL) 184 ± 116 168 ± 58.5 0.411
Low-density lipoprotein cholesterol (mg/dL) 103.3 ± 36.7 105.3 ± 35.7 0.574
High-density lipoprotein cholesterol (mg/dL) 35.9 ± 7.6 36.2 ± 8.7 0.934
Total cholesterol (mg/dL) 179.2 ± 40.6 177.4 ± 37.9 0.891
Abbreviations: GDM Gestational diabetes mellitus.
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groups. Fasting and postprandial blood glucose levels were
significantly higher in the GDM group than in the control
group (p <0.001); however, there were not any significant
differences in lipid parameters between the groups
(Table 1).
Interventricular septum thickness (IVS), posterior wall
thickness (PW), left ventricular end-systolic diameter
(LVESD), left ventricle end-diastolic diameter (LVEDD),
LA diameter and LVEF (p > 0.05) were not significantly
different between the GDM and control groups. IVRT
was significantly extended in the GDM group compared to
the control group (80.8 ± 26.4 vs. 71.59 ± 17.5; p = 0.020);
however, E, A, and E/A rate, E/E’ rate and deceleration
times were significantly different (Table 2).
Simple logistic regression analysis revealed that post-
prandial glucose (mg/dL) (OR = 1.566, 95% CI: 0.815-3.236;Table 2 Comparison of echocardiographic parameters betwee
Variables GDM group (n
Left ventricle end-diastolic diameter (mm) 46.0 ± 5.1
Left ventricle end-systolic diameter (mm) 28.8 ± 6.6
Left ventricular ejection fraction (%) 64.6 ± 5.1
Interventricular septum (mm) 8.8 ± 1.4
Posterior wall (mm) 8.9 ± 1.2
Right ventricular diameter (mm) 27.4 ± 2.6
Left atrium diameter (mm) 32.9 ± 3.8
E wave 0.75 ± 0.2
A wave 0.59 ± 0.1
Deceleration time 192.6 ± 47.3
isovolumetric relaxation time 80.8 ± 26.4
E/A 1.29 ± 0.4
E/E’ 6.7 ± 1.8
Epicardial fat thickness (mm) 7.2 ± 2.5p < 0.001) and epicardial fat thickness (mm) (OR = 1.624,
95% CI: 0.815-3.236; p < 0.001 showed a trend (p < 0.10)
toward an association with the presence of GDM (Table 3).
We entered these variables into a backward stepwise multi-
variate logistic regression model, which demonstrated that
post-prandial glucose and epicardial fat thickness were sig-
nificant and independent predictors of GDM(OR = 1.625,
95% CI: 0.988-2.786; p < 0.001 and OR= 1.524, 95% CI:
0. 0.715-2.958; p < 0.001) (Table 3).
Pearson’s correlation analysis showed that EFT was
positively correlated with the post-prandial glucose
level (p < 0.001) and BMI in both the groups (p < 0.01)
(Figures 1 and 2). Correlation between EFT and other
variables are shown in Table 4. Multiple stepwise regres-
sion analysis showed that only post prandial glucose
(r = 0.627, p < 0.001) and BMI (r = 0.264, p < 0.01) signifi-
cantly associated with serum EFT.n the groups
: 65) Control group (n: 64) p-value
46.6 ± 4.5 0.675
30.4 ± 3.0 0.224
62.9 ± 4.5 0.205
8.7 ± 1.6 0.682
9.0 ± 1.5 0.823
27.5 ± 2.4 0.654
32.8 ± 2.7 0.784
0.77 ± 0.2 0.685
0.57 ± 0.1 0.065
181.4 ± 25.6 0.112
71.59 ± 17.5 0.020
1.38 ± 0.3 0.141
6.1 ± 2.3 0.193
5.6 ± 1.7 <0.001
Table 3 Logistic regression analysis for the presence of GDM in pregnancy
Simple regression OR (95% CI) p-value Multiple regression OR (95% CI) p-value
Age (years) 0.979 (0.915-1.048 0.538
Post-prandial glucose (mg/dL) 1.566 (0.965-2.862) <0.001 1.625 (0.988-2.786) <0.001
Body mass index (kg/m2) 1.125 (0.848-1.494) 0.414
Heart rate (beats/minute) 1.095 (1.011-1.186) 0.266
Epicardial fat thickness (mm) 1.624 (0.815-3.236) <0.001 1.524 (0.715-2.958) <0.001
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We used TTE to measure EFT in pregnant women with
and without GDM and observed two significant findings:
EFT was significantly higher in the GDM group, and it was
significantly correlated with the post-prandial glucose level.
Among the factors associated with GDM, visceral obes-
ity is a major risk factor. Progressive increase in intra-
abdominal fat tissue causes insulin resistance in liver and
adipose tissue, and, as a result, causes glucose intolerance,
low-level HDL, elevated triglycerides and hypertension
[23,24]. Since, epicardial fat tissue originates from visceralFigure 1 The correlation analysis of postprandial glucose levels and efat tissue, the present study was conducted to investigate
the hypothesis that EFT might be elevated in patients with
GDM. Several methods are used to measure EFT in
systole and diastole. Some researchers favor investigator-
dependent methods such as echocardiography, whereas
others prefer investigator-independent methods such as
multislice computed tomography. In the present study, we
used TTE to measure EFT.
Epicardial adipose tissue is not only a physiological
barrier, but is also a bioactive organ that produces
several inflammatory cytokines and adipokines [25,26].picardial fat thickness in both the groups.
Figure 2 The correlation analysis of BMI levels and epicardial fat thickness in both the groups.
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mechanisms such as insulin resistance, endothelial
dysfunction, atherosclerosis, and obesity. There is a
relationship between EFT, abdominal visceral obesity,
subclinical atherosclerosis, impaired fasting glucose, type
1 DM, and hypertension [27-31]. The negative glucose
profile in epicardial fat tissue is affected by the levels of
glucose transporter-4 and retinol-binding protein [32].
Moreover, mRNA expression is related to epicardial fat,
plasma insulin, and insulin-resistance-related molecule
resistance [25]. The negative effects of EAT on glucoseTable 4 The univariate correlations of the epicardial
fat thickness
Variables r-value p-value
Postprandial glucose (mg/dL) 0.66 <0.001
Body mass index (kg/m2) 0.26 <0.01
Heart rate (beats/minute) 0.25 0.01
Age (years) 0.19 0.04
Abbreviations: BMI Body mass index.metabolism are also associated with the studies performed
in patients with DM [11].
Caliskan et al. [33] showed that patients who previously
had GDM showed elevated EAT compared to patients in
the control group. Moreover, the authors concluded that
patients with a history of GDM also had atherosclerosis.
Elevated EFT can further complicate GDM because
EFT is also a risk factor for coronary artery disease. Kim
et al. [34] used cardiovascular magnetic resonance (CMR)
to show that an increase in EFT is an independent risk
factor for coronary artery stenosis in patients with asymp-
tomatic type 2 DM. Wang et al. [35] used cardiac multi-
slice CT to describe the relationship between EFT volume
and metabolic syndrome and coronary atherosclerosis. In
another study, Bachar et al. [36] used a multidetector CT
to investigate EFT, coronary calcium score and coronary
artery stenosis, and reported that EFT is a strong predictor
of coronary artery disease.
DM affects the diastolic functions of the heart, and
uncontrolled hyperglycemia provokes the diastolic left
ventricular dysfunction in type 2 diabetic patients
Nar et al. Diabetology & Metabolic Syndrome 2014, 6:120 Page 6 of 7
http://www.dmsjournal.com/content/6/1/120without cardiac involvement [37,38]. Left ventricular
diastolic function changes are associated with fasting
plasma glucose levels and glycohemoglobin concentrations
under the diabetes threshold [39]. The IVRT elongation
observed in the GDM group in the present study can be
attributed to the negative effects of hyperglycemia on the
diastolic functions of the heart.
In the present study, we observed a strong positive
correlation between EFT and postprandial glucose levels.
Echocardiography and CT studies show a strong correl-
ation between fasting plasma glucose and EFT [40]. In the
present study, we showed a relationship between the post-
prandial glucose level and EFT, which might have been
due to the relationship between EFT and hyperglycemia-
insulin resistance, as described above. Our study corrobo-
rated the results of a previous study that showed that BMI
and EFT have a weak correlation. Bettencourt et al. [41]
showed that EFT is directly related to gender, age, BMI,
waist circumference, abdominal visceral fat tissue, and
atherosclerotic load. EFT is associated with BMI in
females with DM [11] and was higher in females with a
BMI >27 kg m−2 [16]. Moreover, EFT is an independent
predictor of intra-abdominal visceral fat tissue [42-44].
The correlation between EFT and BMI is an expected
finding, as EFT is a parameter indicative of adipose tissue.
However, our study showed that BMI is weakly correlated
with EFT. This can be attributed to the weight gain and
the changes in body composition during pregnancy. These
changes include the changes in adipose tissue and RBC
mass, body water, uterine and breast tissue, and the prod-
ucts of conception including the fetus, placenta and amni-
otic fluid [45]. The increased visceral adipose tissue has a
decreased effect on weight gain during pregnancy, which
may cause the weak correlation between BMI and epicar-
dial adipose tissue.Limitations of the study
Measurement of EFT is routinely used during echocar-
diographic examination. This is an observational study.
In addition to the adipose tissue, pregnancy-associated
weight gain and significant changes in body composition
affect EFT related parameters such as waist circumference,
anthropometric measurements and BMI. Studies involving
pre- and post-pregnancy follow-ups may help us under-
stand the cause and effect relationship.Conclusion
This study shows that TTE measured EFT is higher in
patients with GDM. Moreover, a strong correlation
between EFT and the postprandial glucose levels was
found. These findings can be helpful to understand the
physiopathology of GDM; however, further studies are
necessary to support this conclusion.Competing interests
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